Download PDF

1. Company Snapshot

1.a. Company Description

Certara, Inc.provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access.It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.


The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market.Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access.Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform.


The company serves biopharmaceutical companies, and academic and government institutions.It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.Certara Inc.


was founded in 2008 and is headquartered in Princeton, New Jersey.

Show Full description

1.b. Last Insights on CERT

Certara, Inc.'s recent performance was negatively impacted by its Q4 2025 earnings miss, with quarterly earnings of $0.09 per share, lagging behind the Zacks Consensus Estimate of $0.11 per share. Despite a 9% revenue growth in FY 2025, reaching $418.8M, and a 10% growth in Adj. EBITDA to $134.5M, the company's guidance and earnings miss likely affected its performance. Additionally, a "Moderate Buy" rating from analysts, with a potential upside of 43.3% (source: Wall Street analysts, Marketbeat.com), may have influenced investor sentiment.

1.c. Company Highlights

2. Certara's Earnings Report: A Mixed Bag

Certara's financial performance for the fourth quarter of 2025 was marked by revenue growth of 3% to $103.6 million, with software revenue increasing by 10% to $46.4 million. However, adjusted EBITDA decreased to $32.5 million from $33.5 million in the prior year period. The company's EPS came in at $0.09, below estimates of $0.11. The revenue growth was driven by the company's software and services segments, with bookings increasing by 7% to $155.2 million.

Publication Date: Feb -27

📋 Highlights
  • Leadership Vision & Strategic Focus:: Jon Resnick, Certara’s new CEO, emphasized AI-driven drug development platforms and model-informed methodologies as key growth drivers, aligning with industry needs to reduce $200B+ drug development costs and accelerate timelines.
  • Regulatory Momentum:: Certara’s model-informed approaches gain traction as regulators (e.g., FDA) increasingly support computational methods, evidenced by 23 agencies using its technologies and 430+ PhD/MD experts contributing to drug approvals.
  • 2025 Financial Performance:: Q4 revenue reached $103.6M (+3% YoY), with software revenue up 10% to $46.4M, though software bookings dipped 6% to $56.1M and adjusted EBITDA declined slightly to $32.5M.
  • 2026 Guidance:: Revenue expected to grow 0–4% YoY, with adjusted EBITDA margin targeting 30–32% despite R&D investments; EPS guidance of $0.44–$0.48 reflects tax rate of ~30% and share count of 160–162M shares.
  • Operational Priorities:: Strategic initiatives include portfolio focus, customer-centric operations, and AI integration to boost productivity, alongside addressing Q1 booking challenges due to prior-year comparisons and market timing delays.

Segment Performance

The software segment saw a 10% increase in revenue, driven by the company's differentiated and deeply embedded software solutions. The services segment, on the other hand, saw a 1% decline in revenue. The company's QSP and PBPK businesses are expected to drive growth in the services segment, with the FDA's push towards more computational and modeling-based approaches.

Guidance and Outlook

The company has guided to flat to low single-digit revenue growth in 2026, with adjusted EBITDA margin expected to be in the range of 30% to 32%. The guidance reflects both market conditions and operational improvements planned by the company. Analysts estimate next year's revenue growth at 7.1%, which is slightly higher than the company's guidance.

Valuation

Certara's valuation metrics suggest that the company is trading at a discount to its peers. The P/S Ratio of 2.59 and EV/EBITDA of 20.37 suggest that the company's revenue and EBITDA growth are not fully reflected in its stock price. However, the P/E Ratio is negative due to the company's historical losses. The company's Return on Equity (ROE) is -0.15%, and Return on Invested Capital (ROIC) is -0.31%, indicating that the company is still in the process of improving its profitability.

Regulatory Environment

The FDA's push towards more computational and modeling-based approaches is expected to drive growth in Certara's QSP and PBPK businesses. As Jon Resnick mentioned, "the FDA is pushing towards more computational and modeling-based approaches, and we're seeing a shift towards our services in this area." This shift is expected to benefit Certara's offerings and drive growth in the company's services segment.

3. NewsRoom

Card image cap

Certara, Inc. (CERT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar -10

Source: seekingalpha.com

Card image cap

Certara, Inc. (CERT) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar -09

Source: seekingalpha.com

Card image cap

Certara CEO Resnick Teases Regulatory Services Decision, Phoenix Cloud Push at TD Cowen Conference

Mar -09

Source: defenseworld.net

Card image cap

Certara, Inc. (CERT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar -03

Source: seekingalpha.com

Card image cap

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Mar -03

Source: globenewswire.com

Card image cap

Touchstone Small Cap Fund Q4 2025 Portfolio Review

Mar -02

Source: seekingalpha.com

Card image cap

Certara to Participate in Upcoming Investor Conferences

Feb -27

Source: globenewswire.com

Card image cap

Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.87%)

6. Segments

Services

Expected Growth: 7.5%

Certara's 7.5% growth driven by increasing adoption of model-informed drug development, rising demand for biosimulation and regulatory writing services, expansion into new therapeutic areas, and strategic partnerships with biopharmaceutical companies.

Software

Expected Growth: 8.5%

Certara's software growth is driven by increasing adoption in pharmaceutical R&D, rising demand for model-informed drug development, and expansion into new markets such as biotech and academia. Additionally, the company's strategic acquisitions and partnerships have enhanced its product offerings, contributing to the 8.5% growth rate.

7. Detailed Products

Simcyp Simulator

A platform that simulates clinical trials to predict the behavior of new drugs in virtual populations

PK-Sim

A software that predicts the pharmacokinetics of new drugs in various populations

Certara University

A training and education platform that provides courses and certifications in pharmacometrics and model-informed drug development

BaseCase Portal

A cloud-based platform that enables the creation and deployment of interactive, data-driven models and dashboards

Evidence & Access

A consultancy that provides strategic guidance on market access, health economics, and outcomes research

Model-Informed Drug Development (MIDD) Services

A consultancy that provides strategic guidance on model-informed drug development, including pharmacometrics, and clinical trial design

8. Certara, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Certara, Inc. has a moderate threat of substitutes due to the availability of alternative products and services in the market.

Bargaining Power Of Customers

Certara, Inc. has a low bargaining power of customers due to the lack of concentration of buyers in the market.

Bargaining Power Of Suppliers

Certara, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market.

Threat Of New Entrants

Certara, Inc. has a high threat of new entrants due to the low barriers to entry in the market.

Intensity Of Rivalry

Certara, Inc. operates in a highly competitive market, leading to a high intensity of rivalry among competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 21.77%
Debt Cost 7.66%
Equity Weight 78.23%
Equity Cost 12.00%
WACC 11.05%
Leverage 27.82%

11. Quality Control: Certara, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Progyny

A-Score: 5.3/10

Value: 3.6

Growth: 8.1

Quality: 6.6

Yield: 0.0

Momentum: 10.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Doximity

A-Score: 4.6/10

Value: 1.3

Growth: 8.9

Quality: 9.5

Yield: 0.0

Momentum: 5.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
GoodRx

A-Score: 3.8/10

Value: 6.5

Growth: 5.9

Quality: 7.1

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Certara

A-Score: 3.5/10

Value: 3.3

Growth: 5.9

Quality: 5.7

Yield: 0.0

Momentum: 3.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
10x Genomics

A-Score: 3.4/10

Value: 5.8

Growth: 3.1

Quality: 4.0

Yield: 0.0

Momentum: 5.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
R1 RCM

A-Score: 2.9/10

Value: 3.3

Growth: 3.8

Quality: 2.6

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.66$

Current Price

6.66$

Potential

-0.00%

Expected Cash-Flows